Clinical significance of programmed cell death ligand-1 (PD-L1) expression in immune cells and soluble PD-L1 in blood of ganstrointestinal cancer patients

Clinical significance of programmed cell death ligand-1 (PD-L1) expression in immune cells and soluble PD-L1 in blood of ganstrointestinal cancer patients - PD-L1 expression in immune cells and soluble PD-L1 in gastrointestinal cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023524

Enrollment

Registered

2016-08-08

Start date

2016-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancer (Esophagial cancer,Gastric cancer, pancreatic cancer, liver cancer,billiary tract cancer, colorectal cancer)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as esophagial cancer, gastric cancer, pancreatic cancer, billiary tract cancer, or colorectal cancer. Patients who have agreed to provide their blood for this study.

Exclusion criteria

Exclusion criteria: Patients who have not agreed to provide their blood for this study.

Design outcomes

Primary

Measure	Time frame
Correlation between PD-L1 expression in immune cells and soluble PD-L1 value. Correlation between PD-L1 expression in immune cells or soluble PD-L1 value and PD-L1 expression in tumor tissue. Characterstics of PD-L1 expression in immune cells or soluble PD-L1 value in each gastrointestinal cancer type.	—

Secondary

Measure	Time frame
PD-L1 expression in immune cells or blood soluble PD-L1 value as a new biomarker for specific clinico-pathological features in gastrointestinal cancers.	—

Countries

Japan

Contacts

Public ContactSadamu SADAMU HOMMA

Jikei University School of Medicine Division of Oncology

sahya@jikei.ac.jp03-3433-1111

Outcome results